|
THE
notion of generic drugs being cheap, of low quality and
ineffective will vanish as India’s third-largest
pharmaceutical company, Dr. Reddy’s Laboratories Ltd.,
distributes its own perfected drug-formulation
technology to the Philippines with a price cut of 50
percent compared with branded medicine offered by
foreign multinational drug companies.
In
partnership with Britton Marketing Corp., Dr. Reddy’s
will target medications for cardiovascular disorders,
diabetes, infectious diseases and deadly cancer.
Generic
drugs for Omeprazole, Amlodipine maleate, Losartan,
Gliclazide, Ramipril, Meloxicam, Ciprofloxacin and
Finasteride will now be available in leading drugstores
like Mercury Drug, Watsons and the like without
draining the people’s budget.

RAJESH Kumar, regional head
of AMEERA and senior director of Dr. Reddy’s, talks
about the discovery of Dr. Reddy’s core purpose and its
promise of a healthier life and ensuring that essential
medicines are available, accessible and affordable to
the greater number of Filipinos during Dr. Reddy’s
company launch at the Edsa Shangri-La Hotel in
Mandaluyong City.
--RHOY COBILLA
In the
Asean, Dr. Reddy’s already has presence in Myanmar,
Vietnam, Cambodia, Malaysia, Singapore and Thailand.
Humble Rajesh Kumar, Dr. Reddy’s senior director and
region head for AMEERA’s (Asean, Middle East, Eastern
Europe, Rest of Africa) even apologized to Filipinos for
its late entry in the Philippines.
“Affordability, availability and accessibility to
quality medicines, plus our core purpose to help people
lead healthier lives, are our goals to be always
served,” told Kumar in an interview with BusinessMirror.
Kumar
sees the Filipino culture of lacking trust in generic
medicines as a growth potential and a challenge to
penetrate the country’s pharmaceutical market, which is
close to P90 billion.
“Dr.
Reddy’s credibility is backed by our global presence in
over 100 countries and strict compliance to manufacture
drugs at par,” explained Kumar.
“With
the help, of course, of our manufacturing facilities
overseas,” added Antony Raj Gomes, Dr. Reddy’s senior
director for quality control.
Dr.
Reddy’s not only promised to lower medicine costs but to
also employ Filipinos and engage others in livelihood
advance business schools (LABS)—one of the corporate
social responsibility programs started by Dr. Anji
Reddy, the founder and chairman of Dr. Reddy’s.
“We are
going to employ 40 Filipinos from managerial positions
down to salespersons,” said Kumar.
Gomes
added, “The LABS project will be coordinated with the
local government soon.”
Health
Undersecretary Dr. Ethelyn Nieto lauded the entry of Dr.
Reddy’s to the country as timely and appropriate, as
House Bill 307, known as the cheap medicine bill, aimed
at reducing the cost of drugs in the country, though
given priority status by the Legislative-Executive
Advisory Council (Ledac), is still on the deliberations
stage.
“It’s
just time the vicious barrier on medicine cost is
broken. This envisions that there will be no more people
who will die because he is refused and not medically
attended to by a hospital due to financial constraints,
or die because he cannot afford to buy medicine,” he
said.
Nieto
sees that the Indian company is the answer to the high
cost of branded medicine sold by multinational
pharmaceuticals.
“Now
that Dr. Reddy’s is here, we don’t have to buy the
soaring medicine prices of multinationals. In 2020, all
Filipinos will no longer be deprived of medicine,” said
Nieto. |